Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome

Cancer

Volumn 119, Issue 1, 2013, Pages 215-225

  Kuppermann, Miriam ^a   Wang, Grace ^b   Wong, Shirley ^a   Blanco, Amie ^a   Conrad, Peggy ^a   Nakagawa, Sanae ^a   Terdiman, Jonathan ^a   Ladabaum, Uri ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMERICAN INSTITUTES FOR RESEARCH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

decision making; genetic testing; hereditary nonpolyposis colorectal cancer; Lynch syndrome; quality of life; utilities

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO HEALTH; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; COLON RESECTION; COLORECTAL SURGERY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; GENETIC SCREENING; HEALTH CARE UTILIZATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION;

ADULT; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SIBLINGS;

EID: 84872780465     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27634     Document Type: Article

References (18)

1. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81: 214-218.
2. Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the lynch syndrome: Diagnostic, surveillance and management implications. Eur J Hum Genet. 2006; 14: 390-402.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening. Fort Washington, PA: NCCN; 2011.
4. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118: 829-834.
5. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med. 2006; 354: 261-269.
6. Linder-Pelz S,. Toward a theory of patient satisfaction. Soc Sci Med. 1982; 16: 577-582.
7. Collins VR, Meiser B, Ukoumunne OC, Gaff C, St John DJ, Halliday JL,. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: Three years after testing. Genet Med. 2007; 9: 290-297.
8. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kääriä inen H,. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): A prospective follow-up study. Int J Cancer. 2001; 93: 608-611.
9. Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005; 23: 1902-1910.
10. Keller M, Jost R, Haunstetter CM, et al. Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet. 2008; 74: 414-424.
11. Carlsson C, Nilbert M,. Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns. 2007; 16: 811-820.
12. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med. 2011; 155: 69-79.
13. Mvundura M, Grosse SD, Hampel H, Palomaki GE,. The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010; 12: 93-104.
14. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila). 2011; 4: 9-22.
15. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A,. Psychological side effects of breast cancer screening. Health Psychol. 1991; 10: 259-267.
16. Wu JM, Fulton RG, Amundsen CL, Knight SK, Kuppermann M,. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg. 2011; 17: 184-189.
17. Torrance GW,. Measurement of health state utilities for economic appraisal. J Health Econ. 1986; 5: 1-30.
18. Kuppermann M, Nease RF Jr, Gates E, et al. How do women of diverse backgrounds value prenatal testing outcomes? Prenat Diagn. 2004; 24: 424-429.